The average one-year price target for Sight Sciences (NasdaqGS:SGHT) has been revised to $9.54 / share. This is an increase ...

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...

Sight Sciences, Inc.'s share price has fallen by -13.3% in the past 3 weeks, despite reporting a narrower-than-expected net loss in Q1 and sticking to its 2023 guidance. Sight Sciences' key Q1 2023 ...

) has been revised to $8.01 / share. This is an increase of 22.34% from the prior estimate of $6.55 dated December 3, 2025. The price target is an average of many targets provided by analysts. The ...

Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $95 and keeps a Buy rating on the shares. Although the company’s Q3 results and reduction to 2024 ...

Roivant Sciences (NASDAQ:ROIV) prices an upsized underwritten public offering of 26.66M shares at a price of $7.50 per share. The gross proceeds are expected to be $200M. Underwriters have a 30-day ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...

Canaccord raised the firm’s price target on Exact Sciences (EXAS) to $95 from $75 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness ...